Immunotherapy Focus Ukko is pursuing safe immunotherapies to rapidly treat allergies and immune-mediated conditions, presenting a sales angle for partnerships or contracts with pharma, CROs, and healthcare providers seeking advanced allergy solutions and safer desensitization alternatives.

AI and Protein Engineering The company leverages artificial intelligence and protein engineering to design therapies, offering opportunities to sell AI-driven discovery tools, data services, or collaboration on precision allergen immunotherapies to biotech platforms and R&D teams.

Funding and Growth With a Series B funding of 40 million led by Leaps by Bayer and a growing team, Ukko signals scale-up potential and willingness to partner on development, manufacturing, or clinical studies for allergen-focused programs.

Market Positioning Ukko targets life-threatening peanut allergy risk and allergic reactions reduction, presenting a niche but high-value market. Potential sales angles include regulatory strategy support, clinical trial services, and safety-focused product development collaborations.

Geographic and Talent Footprint Based in Tel Aviv with 51-200 employees, Ukko may need regional partnerships in markets with strong biotech ecosystems and access to talent and manufacturing capabilities, offering opportunities for regional distributors, contract manufacturers, or local regulatory consultants.